Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Innoviva Inc (INVA)  
$16.08 0.07 (0.43%) as of 4:30 Wed 5/22


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 101,390,000
Market Cap: 1.63(B)
Last Volume: 668,805 Avg Vol: 666,964
52 Week Range: $12.32 - $16.78
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Innoviva is a company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®. Co. is entitled to royalty payments made by GSK under its agreements that assigned to Theravance Respiratory Company, LLC (TRC), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the Long-Acting Beta2 Agonist Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 215,000 664,000
Total Buy Value $0 $0 $2,804,388 $8,468,005
Total People Bought 0 0 1 2
Total Buy Transactions 0 0 5 12
Total Shares Sold 0 0 10,994 10,994
Total Sell Value $0 $0 $153,810 $153,810
Total People Sold 0 0 1 1
Total Sell Transactions 0 0 1 1
End Date 2024-02-22 2023-11-21 2023-05-23 2022-05-23

   
Records found: 704
  Page 16 of 29  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Winningham Rick E Chief Executive Officer   •       •      –    2012-10-15 4 A $0.00 $0 D/D 11,000 591,577     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2012-10-15 4 A $0.00 $0 D/D 5,000 212,641     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2012-10-15 4 A $0.00 $0 D/D 5,000 342,624     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2012-10-15 4 A $0.00 $0 D/D 5,000 137,486     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2012-08-27 4 AS $27.24 $561,855 D/D (20,561) 132,486     -
   Brinkley David L Head of Business Dev.   •       –      –    2012-08-24 4 AS $27.50 $95,783 D/D (3,483) 60,241     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2012-08-24 4 AS $28.01 $115,429 D/D (4,121) 153,047     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2012-08-24 4 OE $17.91 $73,807 D/D 4,121 157,168     -
   Winningham Rick E Chief Executive Officer   •       •      –    2012-08-20 4 D $27.01 $288,494 D/D (10,681) 580,577     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2012-08-20 4 D $27.01 $124,138 D/D (4,596) 337,624     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2012-08-20 4 D $27.01 $131,728 D/D (4,877) 153,047     -
   Brinkley David L Head of Business Dev.   •       –      –    2012-08-20 4 D $27.01 $82,570 D/D (3,057) 63,724     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2012-08-20 4 D $27.01 $125,434 D/D (4,644) 207,641     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2012-08-13 4 AS $25.68 $643,461 D/D (25,000) 212,285     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2012-08-07 4 AS $27.04 $1,622,400 D/D (60,000) 157,924     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2012-08-07 4 OE $16.25 $975,000 D/D 60,000 217,924     -
   Winningham Rick E Chief Executive Officer   •       •      –    2012-08-03 4 AS $27.77 $2,117,306 D/D (75,749) 591,258     -
   Winningham Rick E Chief Executive Officer   •       •      –    2012-08-03 4 OE $3.10 $449,999 D/D 145,161 667,007     -
   Brinkley David L Head of Business Dev.   •       –      –    2012-08-03 4 AS $27.92 $3,459,763 D/D (123,917) 66,781     -
   Brinkley David L Head of Business Dev.   •       –      –    2012-08-03 4 OE $6.15 $840,955 D/D 106,757 190,698     -
   Glaxosmithkline Plc 10% Owner   –       –       •   2012-08-03 4 B $28.21 $8,923,782 I/I 316,334 26,130,755 1.5     -
   Blum Leonard M Sr VP, Chief Comm. Officer   •       –      –    2012-07-30 4 D $29.69 $224,041 D/D (7,546) 279,386     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2012-05-29 4 S $22.29 $445,800 D/D (20,000) 157,924     -
   Winningham Rick E Chief Executive Officer   •       •      –    2012-05-20 4 D $20.33 $217,145 D/D (10,681) 521,846     -
   Brinkley David L Head of Business Dev.   •       –      –    2012-05-20 4 D $20.33 $48,833 D/D (2,402) 83,941     -
  704 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 16 of 29
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us